TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06219369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group T
Description: SPSIPB Technique:~The SPSIPB block, which follows the guidelines we routinely use, will be performed after the completion of the surgical procedure and before the patient wakes up.~TPVB Technique:~The US probe (11-12 MHz, Vivid Q) will be placed 2-3 cm lateral to the T5 spinous process. After visualizing the transverse process, the paravertebral area, internal intercostal membrane, paravertebral space, and pleura, the needle will be advanced to the paravertebral space using an in-plane technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group T
Description: SPSIPB Technique:~The SPSIPB block, which follows the guidelines we routinely use, will be performed after the completion of the surgical procedure and before the patient wakes up.~TPVB Technique:~The US probe (11-12 MHz, Vivid Q) will be placed 2-3 cm lateral to the T5 spinous process. After visualizing the transverse process, the paravertebral area, internal intercostal membrane, paravertebral space, and pleura, the needle will be advanced to the paravertebral space using an in-plane technique.
Study: NCT06300528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.
Study: NCT05237128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet
Description: Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month.
Study: NCT00992238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavoxate Hydrochloride Tablets, 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urispas® Tablets, 100mg
Study: NCT05572801

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AMR B: HPV positive ctDNA guided imaging in follow-up
Description: Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure
Study: NCT05237128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate plate-method diet
Description: Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month.
Study: NCT05022862

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Medication is dispensed to participant at each visit in 30-60 day supplies by Baltimore City Health Department (BCHD) nurses. For study participants, medication dispensation will occur in medication bottles with MEMS Caps, supplied by the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Medication is dispensed to participant at each visit in 30-60 day supplies by Baltimore City Health Department (BCHD) nurses. For study participants, medication dispensation will occur in medication bottles with MEMS Caps, supplied by the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Medication is dispensed to participant at each visit in 30-60 day supplies by Baltimore City Health Department (BCHD) nurses. For study participants, medication dispensation will occur in medication bottles with MEMS Caps, supplied by the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Directly Observed Therapy alone
Description: Usual care plus Video-DOT using the emocha platform, a HIPAA compliant commercial platform for video based DOT. The app allows a secure/encrypted video recording to be taken as the participant ingests the medication. Electronic text reminders will be sent to the participant on the smart phone when it is time to take the medication. The participant will record a video of the pill ingestion process. Study staff will verify each video to confirm the video shows the correct person and that the pill was ingested appropriately (according to standardized approach involving visualization of the pills, ingestion and observation of an empty mouth after ingestion).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Directly Observed Therapy alone
Description: Usual care plus Video-DOT using the emocha platform, a HIPAA compliant commercial platform for video based DOT. The app allows a secure/encrypted video recording to be taken as the participant ingests the medication. Electronic text reminders will be sent to the participant on the smart phone when it is time to take the medication. The participant will record a video of the pill ingestion process. Study staff will verify each video to confirm the video shows the correct person and that the pill was ingested appropriately (according to standardized approach involving visualization of the pills, ingestion and observation of an empty mouth after ingestion).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Directly Observed Therapy plus Financial Incentives
Description: Usual care plus video-DOT and financial incentives contingent on adherence verified by video DOT. The amount of the financial incentive that can be earned for future verified doses decreases after a missed dose (video). The amount of the financial incentives increases incrementally back to baseline amount after verification of medication ingestion according to the prescribed schedule for several consecutive doses.
Study: NCT05612048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-oral camera
Description: Intraoral pictures of molars and incisors in 13 key regions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-oral camera
Description: Intraoral pictures of molars and incisors in 13 key regions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-oral camera
Description: Intraoral pictures of molars and incisors in 13 key regions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optional Salvia sample
Description: Cohort 1 only. Participant is responsible for collecting and bringing the salvia sample to clinic.
Study: NCT06241989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education supported by motivational interviewing
Description: The intervention group will receive health education supported by motivational interviewing consisting of 6 sessions. Within the scope of the intervention, the first two sessions will be health education and the last four sessions will be motivational interviewing.
Study: NCT05185830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive robots
Description: Children will mobilize with the interactive robot when control group will mobilize with nurse.
Study: NCT05938387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 12 μg
Description: CVGBM will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 25 μg
Description: CVGBM will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 50 μg
Description: CVGBM will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 100 μg
Description: CVGBM will be administered as an IM injection.
Study: NCT06084169

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra Ocular Lens (IOL) Implant
Description: Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra Ocular Lens (IOL) Implant
Description: Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye
Study: NCT06522269

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Emergency Stroke Unit based on 0.23-T MRI
Description: The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Standard stroke unit adherent to guidelines
Description: The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
Study: NCT06027567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet
Description: Very Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietician counselling
Description: Counselling by a dietician on weight loss through behavioural changes and life style intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietician counselling
Description: Counselling by a dietician on weight loss through behavioural changes and life style intervention
Study: NCT04600713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PT-X and IMT
Description: The intervention consists of PT-X, including central circulatory exercise and muscle exercises, 2 times/week, 60 min/session for 12 weeks, and homebased exercises 2 times/week logged in an exercise diary. For IMT the Threshold Inspiratory Muscle Trainer (Threshold IMT) (Respironics Inc., Murrysville, PA, USA) will be used at 30 % of maximal expiratory pressure in 15 minutes 2 times a day during 12 weeks.
Study: NCT05699226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix Medical Incorporated 4x1 adapter
Description: Device permits individualized amplitudes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ECT device
Description: FDA approved ECT device with fixed amplitude.
Study: NCT05938387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine RDE 100 μg
Description: CVGBM will be administered as an IM injection.
Study: NCT05892341

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® Ag+ Extra™
Description: Wound treatment with AQUACEL® Ag+ Extra™ dressing
Study: NCT05938387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 6 μg
Description: CVGBM will be administered as an IM injection.
Study: NCT05892341

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutimed® Sorbact®
Description: Wound treatment with Cutimed® Sorbact® dressing
Study: NCT05176509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be administered intravenously over 60 minutes every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: YH001 will be administered intravenously over 60 minutes every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
Study: NCT05623488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huCART-meso cells
Description: Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huCART-meso cells
Description: Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesothelin Expression Testing
Description: Laboratory Developed Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesothelin Expression Testing
Description: Laboratory Developed Test
Study: NCT05703230

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured preoperative multidisciplinary team meeting
Description: The intervention to be investigated is the introduction of a preoperative structured multidisciplinary team (sMDT) meeting for high risk noncardiac surgical patients, which is attended by at least the treating surgical specialist, an anesthesiologist and another medical consultant with expertise relevant for the patients comorbidities and preferences. In the preoperative sMDT meeting, at least the following questions will be discussed as recommended by the Dutch Perioperative Guideline:~* Is the proposed surgical intervention appropriate care for the patient?~* Is the risk/benefit ratio of the proposed surgical intervention acceptable for the patient?~* Should the patient's condition be optimized before undergoing the proposed surgical intervention?
Study: NCT05763342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Phoenix Research System
Description: Focused Multipolar Stimulation (FMS) strategy in adult cochlear implant recipients.
Study: NCT05054673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: universal adhesive
Description: PALFIQUE universal adhesive

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: universal adhesive
Description: 3M™ ESPE™ single bond Universal Adhesive
Study: NCT05685641

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histoplasma Urine Antigen Lateral Flow Antigen test
Description: Lateral Flow Antigen test for urine samples to detect Histoplasma capsulatum disseminated disease

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cryptococcal Lateral Flow Antigen test
Description: Lateral Flow Antigen test for serum or cerebrospinal fluid samples to detect Cryptococcus sp meningitis or disseminated disease

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tuberculosis-lipoarabinomannan Lateral Flow Antigen test
Description: Lateral Flow Antigen test for serum samples to detect Mycobacterium tuberculosus disease
Study: NCT06281782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical retinoids and platalet rich plasma
Description: We will analyse both monotherapy with a topical retinoid alone and combination therapy with a topical retinoid and platelet-rich plasma (PRP) to elucidate their role in acne treatment and provide possible recommendations for their use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical retinoids and platalet rich plasma
Description: We will analyse both monotherapy with a topical retinoid alone and combination therapy with a topical retinoid and platelet-rich plasma (PRP) to elucidate their role in acne treatment and provide possible recommendations for their use.
Study: NCT04933721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: berotralstat
Description: BCX7353 capsules administered orally once daily
Study: NCT05214898

Intervention type: BEHAVIORAL
Intervention: 24/7 Dad
Description: The 24/7 Dad curriculum is an evidence-based, skills driven curriculum (12 group sessions). The following topics are included: Family History, What it Means to Be a Man, Showing and Handling Feelings, Men's Health, Communication, The Father's Role, Discipline, Children's Growth, Getting Involved, Working with \& Co-Parenting, Dads and Work, and the My 24/7Dad Checklist. Healthy Relationship topics include: Communication Skills, including expression, discussion, and negotiation skills; Conflict Resolution and Anger Management; Problem-Solving; and Knowledge of the Benefits of Marriage. Responsible Parenting areas of focus include: children's growth/development; non-violent discipline; co-parenting; building conflict resolutions skills (for the child and the family); and, enhancing family relationships.

Intervention type: BEHAVIORAL
Intervention: 24/7 Dad
Description: The 24/7 Dad curriculum is an evidence-based, skills driven curriculum (12 group sessions). The following topics are included: Family History, What it Means to Be a Man, Showing and Handling Feelings, Men's Health, Communication, The Father's Role, Discipline, Children's Growth, Getting Involved, Working with \& Co-Parenting, Dads and Work, and the My 24/7Dad Checklist. Healthy Relationship topics include: Communication Skills, including expression, discussion, and negotiation skills; Conflict Resolution and Anger Management; Problem-Solving; and Knowledge of the Benefits of Marriage. Responsible Parenting areas of focus include: children's growth/development; non-violent discipline; co-parenting; building conflict resolutions skills (for the child and the family); and, enhancing family relationships.
Study: NCT05477420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Participants in the experimental group would be asked to use the decision aid developed by the study. The decision aid tool will ask participants their preferences on traditional face-to-face and online psychotherapies and how they rank different treatment attributes.
Study: NCT05093608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor Pill
Description: Selinexor 60 mg or 80 mg (oral table) will be administered once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor Pill
Description: Selinexor 60 mg or 80 mg (oral table) will be administered once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.
Study: NCT04866303

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home-based SARS-CoV-2 test kit
Description: A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home-based SARS-CoV-2 test kit
Description: A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
Study: NCT04407325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic nose device
Description: electronic nose device will be tested as a triage instrument for tuberculosis in a high risk population

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dig chest Xray with automated readings
Description: software for tuberculosis detection on digital Chest Xray providing a probability score from 0-100
Study: NCT05432934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
Study: NCT05948358

Intervention type: OTHER
Intervention: Menstrual Distress Questionnaire
Description: The Menstrual Distress Questionnaire (MEDI-Q) is a new tool originally developed in Italian that comprehensively evaluates menstrual-related distress.
Study: NCT06385886

Intervention type: BEHAVIORAL
Intervention: Linkage Coordinator
Description: The Linkage Coordinator (LC) will be the initial contact with unaffiliated SCD patients to establish a relationship, champion preventative services, and support them in engaging with an SCD specialist by helping patients address barriers to care. Study staff will provide initial and ongoing training to the LC to ensure they have adequate support to effectively engage with patients.
Study: NCT06205693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast Degradable, Biodegradable ARCHEMEDES stent
Description: Fast Degradable, Biodegradable ARCHEMEDES stent. Placed in the pancreaticojejunostomy.
Study: NCT06561139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Weekly group sessions of mindfulness, for eight weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Weekly group sessions of mindfulness, for eight weeks